Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)

被引:150
|
作者
Powell, Chelsea E. [1 ,4 ]
Gao, Yang [5 ,6 ]
Tan, Li [1 ,4 ]
Donovan, Katherine A. [1 ,4 ]
Nowak, Radoslaw P. [1 ,4 ]
Loehr, Amanda [5 ,6 ]
Bahcall, Magda [2 ]
Fischer, Eric S. [1 ,4 ]
Janne, Pasi A. [2 ,3 ]
George, Rani E. [5 ,6 ]
Gray, Nathanael S. [1 ,4 ]
机构
[1] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA
[2] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02215 USA
[3] Dana Farber Canc Inst, Belfer Ctr Appl Canc Sci, Boston, MA 02215 USA
[4] Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA
[5] Harvard Med Sch, Dept Pediat Hematol & Oncol, Dana Farber Canc Inst, Boston, MA 02215 USA
[6] Harvard Med Sch, Childrens Hosp Boston, Boston, MA 02215 USA
基金
美国国家卫生研究院;
关键词
CELL LUNG-CANCER; INHIBITOR; RESISTANCE; POTENT;
D O I
10.1021/acs.jmedchem.7b01655
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
We present the development of the first small molecule degraders that can induce anaplastic lymphoma kinase (ALK) degradation, including in non-small-cell lung cancer (NSCLC), anaplastic large-cell lymphoma (ALCL), and neuroblastoma (NB) cell lines. These degraders were developed through conjugation of known pyrimidine-based ALK inhibitors, TAE684 or LDK378, and the cereblon ligand pomalidomide. We demonstrate that in some cell types degrader potency is compromised by expression of drug transporter ABCB1. In addition, proteomic profiling demonstrated that these compounds also promote the degradation of additional kinases including PTK2 (FAK), Aurora A, FER, and RPS6KA1 (RSK1).
引用
收藏
页码:4249 / 4255
页数:7
相关论文
共 50 条
  • [41] LDK378: A Promising Anaplastic Lymphoma Kinase (ALK) Inhibitor
    Chen, Jianyong
    Jiang, Cheng
    Wang, Shaomeng
    JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (14) : 5673 - 5674
  • [42] Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces
    Huang, Hao
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (11)
  • [43] The Association between the Percentage of Anaplastic Lymphoma Kinase(ALK)-Positive Cells and Efficacy of ALK Inhibitor
    Tanaka, Tae
    Yoshioka, Hiroshige
    Haratani, Koji
    Hayashi, Hidetoshi
    Okamoto, Kunio
    Kaneda, Toshihiko
    Yokoyama, Toshihide
    Takeda, Masayuki
    Kaneda, Hiroyasu
    Nakagawa, Kazuhiko
    Ishida, Tadashi
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1162 - S1162
  • [44] Atypical Carcinoid Tumor with Anaplastic Lymphoma Kinase (ALK) Rearrangement Successfully Treated by an ALK Inhibitor
    Nakajima, Masayuki
    Uchiyama, Naoki
    Shigemasa, Rie
    Matsumura, Takeshi
    Matsuoka, Ryota
    Nomura, Akihiro
    INTERNAL MEDICINE, 2016, 55 (21) : 3151 - 3153
  • [45] Anaplastic Lymphoma Kinase (ALK)-Induced Malignancies: Novel Mechanisms of Cell Transformation and Potential Therapeutic Approaches
    Wasik, Mariusz A.
    Zhang, Qian
    Marzec, Michal
    Kasprzycka, Monika
    Wang, Hong Yi
    Lo, Xiaobin
    SEMINARS IN ONCOLOGY, 2009, 36 (02) : S27 - S35
  • [46] Anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma (ALCL) of breast in a patient without a breast implant
    Sathyanarayanan, Vishwanath
    Lokesh, Kadabur Nagendrappa
    Lakshmaiah, K. C.
    Babu, Govind K.
    Lokanatha, D.
    Babu, Suresh M. C.
    Rao, Clementina Rama
    Chennagiri, Premalata
    ANNALS OF SAUDI MEDICINE, 2014, 34 (06) : 551 - 554
  • [47] From Pathology to Precision Medicine in Anaplastic Large Cell Lymphoma Expressing Anaplastic Lymphoma Kinase (ALK plus ALCL)
    Werner, Michael T.
    Zhang, Qian
    Wasik, Mariusz A.
    CANCERS, 2017, 9 (10):
  • [48] Anaplastic lymphoma kinase (ALK): An important predictor of survival in peripheral T-cell lymphoma
    Aoun, P
    Greiner, T
    Vose, J
    Gordon, B
    Kollath, J
    Morris, S
    Chan, W
    Weisenburger, D
    MODERN PATHOLOGY, 1998, 11 (01) : 125A - 125A
  • [49] Cytologic Findings of Anaplastic Lymphoma Kinase (ALK)-Positive Large B-Cell Lymphoma
    Brandt, Suzanne
    Koreishi, Aashiyana
    Teruya-Feldstein, Julie
    Lin, Oscar
    CANCER CYTOPATHOLOGY, 2010, 118 (05) : 371 - 372
  • [50] Intragenic Anaplastic Lymphoma Kinase (ALK) Rearrangements: Translocations as a Novel Mechanism of ALK Activation in Neuroblastoma Tumors
    Fransson, Susanne
    Hansson, Magnus
    Ruuth, Kristina
    Djos, Anna
    Berbegall, Ana
    Javanmardi, Niloufar
    Abrahamsson, Jonas
    Palmer, Ruth H.
    Noguera, Rosa
    Hallberg, Bengt
    Kogner, Per
    Martinsson, Tommy
    GENES CHROMOSOMES & CANCER, 2015, 54 (02): : 99 - 109